

Memo Therapeutics

Organization

Operational: since Q2/2015

Privately owned, total investment to date:
CHF 7.3m + CHF 2.1m non dilutive

Team: 8 PhD scientists, 3 MSc.


Management

Karsten Fischer, CEO

Christoph Esslinger, CSO & founder

Dragan Grabulovski, Strategy & BD

Active programs




Mission

Develop proprietary antibody therapeutics

Partner Technology

Attract investors (Series B planned for Q4/2019)

Technology platform and products




Successful mAb discovery programs

HUMAN			Rabbit		
Anti-Viral	Anti-Cytokine	Anti-Bacterial	Immuno-Oncology	Tumor Target	IMiD


I-O program targeting receptor of innate & adaptive immune system

Target indication / Market	Drug	Status Memo Therapeutics
<p>4 of top ten solid tumors NSCLC Market: US/Europe: USD > 1bn p.a.</p>	<p>Human monoclonal antibody MoA: De-inhibition of innate and adaptive immune system Risk profile: Target validated</p>	<p>Portfolio of preclin. mAbs: Strong immune-activators Superior to benchmarks</p>


T cell proliferation & activation



Induction of NK cell killing activity




Benign cytokine release profile



I-O program – Next steps & timelines

Preclinical development plan

- PoC in patient-derived-tumors
- PoC in mouse model
- IHC tumor entities
- MoA / Combinations



Investment & Partnering opportunities

